Obesity
MASH
T2DM
Hyperlipidemia
Metabolic
Syndrome
Insulin Resistance
&
Chronic Inflammation

Our Focus

Chronic metabolic and liver diseases represent a significant unmet medical need and a tremendous burden for patients and caregivers worldwide. These diseases broadly share a pathogenic relationship that leads to the development of multiple metabolic comorbidities, complicating patient management and worsening prognosis.

HighTide’s mission is to identify the unmet needs in these inter-related chronic metabolic diseases and liver diseases and translate those needs into new therapeutic solutions.

Driving progress by exploring innovative ways to treat and manage patients

Our focus is on chronic metabolic diseases and liver diseases, in particular those diseases that are driven by insulin resistance and inflammation and require a holistic treatment approach to address comorbid conditions, thereby delivering comprehensive benefits to patients. These diseases include type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatohepatitis (MASH), obesity, and severe hypertriglyceridemia (SHTG). Each of these diseases are interrelated presenting additive risk.

Development of one metabolic disease sparks another

In patients with pre-diabetes, increases in weight, LDL-C, systolic blood pressure, and triglycerides each can contribute to progression to T2DM.1

MASH in the presence of obesity and/or T2DM results in a higher risk of progressive scarring of the liver (fibrosis) in these patients.2

Patients with multiple metabolic diseases are at higher risk of negative outcomes

Metabolic comorbidities such as obesity and diabetes can accelerate the rate of fibrosis progression and increase the risk of negative outcomes.

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and at least 1 additional metabolic syndrome had a 34 times higher proportion of deaths compared to patients with only MASLD.3

Patients with T2DM and MASH are at significantly higher risk of outcomes such as ischemic heart disease, cancer (liver, renal and pancreatic), or death compared to patients with T2DM alone.4

Survival in MASLD Patients Stratified by Number of Comorbid Metabolic Diseases*3
Graph of survival probability and Survival time
*MD = Metabolic disease comorbidities, including diabetes, hypertension, hyperlipidemia, and obesity

References
1. Alvarez S, Coffey R, Mathias PM, Algotar AM. Prediabetes. StatPearls. Treasure Island (FL)2024.
2. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132-8.
3. Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97(13):e0214.
4. Riley DR, Hydes T, Hernadez G, Zhao SS, Alam U, Cuthbertson DJ. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes. Liver Int. 2024;44(10):2538-50.